Nestlé completes acquisition of Aimmune Therapeutics

Nestlé announced the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc’s global pharmaceutical business, the company said in its press release.

“Aimmune will continue to be run from Brisbane, California. Andrew Oxtoby has been named as Aimmune’s President & CEO, along with a new executive leadership team. Oxtoby was previously Aimmune’s Chief Commercial Officer.”

“Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives,” said Greg Behar, CEO of NHSc. “Aimmune’s PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it’s only the beginning. Aimmune’s pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally.”

Trends Stock

Trends Stock provides information about the latest and upcoming trends in the fields of technology, business, education and sports mainly in Pakistan. To keep pace with this fast growing age of development, one can easily build an opinion about the newest trends by scrolling through relevant sections of the website. The first hand reliable data eases the individual to analyze the cutting edge drifts in the related arenas while making any decision.

Previous Post
Next Post

Leave a Reply

Your email address will not be published. Required fields are marked *